Chi Sheng Pharma & Biotech , Ltd Receivables

The latest receivables for 4111.TWO is $380M as of June 2026. That compares with $380M in the prior-year period — down 2.1% year over year. Investors often review this figure alongside Chi Sheng Pharma & Biotech , Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4111.TWO's receivables moved from $380M to $380M — a 2.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chi Sheng Pharma & Biotech , Ltd's operating scale or balance-sheet position.

A receivables figure of $380M for 4111.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4111.TWO's receivables ($380M), review year-over-year change from $380M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.